Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir.
about
Human cytomegalovirus resistance to antiviral drugsCytomegalovirus antivirals and development of improved animal modelsHow I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipientsAntiviral drug resistance: mechanisms and clinical implicationsAntiviral drug resistance of human cytomegalovirus.How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients.Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance.Emerging rapid resistance testing methods for clinical microbiology laboratories and their potential impact on patient management.Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavirMolecular methods for cytomegalovirus surveillance in bone marrow transplant recipients.Cytomegalovirus retinitis and the acquired immunodeficiency syndrome--bench to bedside: LXVII Edward Jackson Memorial Lecture.Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping.Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.Late emergence of A594V and L595W mutations related to ganciclovir resistance in a patient with HCMV retinitis and long-term HIV progressionDiagnostics for herpes simplex virus: is PCR the new gold standard?Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients.The genetic basis of human cytomegalovirus resistance and current trends in antiviral resistance analysis.Detection of Low Frequency Multi-Drug Resistance and Novel Putative Maribavir Resistance in Immunocompromised Pediatric Patients with CytomegalovirusExpression of the human cytomegalovirus UL97 gene in a chimeric guinea pig cytomegalovirus (GPCMV) results in viable virus with increased susceptibility to ganciclovir and maribavir.Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir.Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens.Natural polymorphism of cytomegalovirus DNA polymerase lies in two nonconserved regions located between domains delta-C and II and between domains III and I.The search for new therapies for human cytomegalovirus infections.Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients.Antiviral Drug- and Multidrug Resistance in Cytomegalovirus Infected SCT Patients.Ganciclovir-Resistant Cytomegalovirus Infection in a Kidney Transplant Recipient Successfully Treated with Foscarnet and Everolimus.Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus.Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art.Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene.Letermovir Treatment of Human Cytomegalovirus Infection Antiinfective Agent.Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study.The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral productionMonitoring of cytomegalovirus infection in solid-organ transplant recipients by an ultrasensitive plasma PCR assay.New reporter cell line to evaluate the sequential emergence of multiple human cytomegalovirus mutations during in vitro drug exposureSuccessful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D.The D-form of a novel heparan binding peptide decreases cytomegalovirus infection in vivo and in vitro.Tolerability of up to 200 days of prophylaxis with valganciclovir oral solution and/or film-coated tablets in pediatric kidney transplant recipients at risk of cytomegalovirus disease.Assessment of the Human Cytomegalovirus UL97 Gene for Identification of Resistance to Ganciclovir in Iranian Immunosuppressed PatientsNovel Method Based on Real-Time Cell Analysis for Drug Susceptibility Testing of Herpes Simplex Virus and Human Cytomegalovirus.Detection of Two Drug-Resistance Mutants of the Cytomegalovirus by High-Resolution Melting Analysis.
P2860
Q24556634-278D397D-47BA-4C93-9266-2600D3906CE5Q27000998-678A58B2-30CC-45A2-BE75-3C41E5AAF942Q28069489-07B255B4-7A54-4408-909E-FF9AD6DA4F30Q28282376-E41AC318-FDA7-4538-BD3F-E0507D157D10Q30430427-E1F505B9-7910-4A50-B260-431DB60B78E6Q33592427-6E1339DD-E62B-4EA6-AD4E-82F654EA8930Q33876672-B69219B1-2399-48E3-99F8-6D16E9C6B211Q34342514-7FACB47D-D831-4ADB-A8AD-D59011209794Q34437391-CF67482A-2A8D-44F3-9A0F-D5FD785B8EE2Q34439235-04031D5B-7B0B-4CC9-9858-0403FAAEE7B8Q34670354-65780525-5B41-4569-B38D-DB55175C37F2Q35036076-6B7855EF-0E3D-490C-BAC5-D4D2022BD686Q35635817-93341D02-9601-4AF4-9B41-DADAB37BEFD0Q36057209-45C28C8D-DE72-443A-B309-ECEC85670D95Q36463219-6CF8E800-1198-4136-BA17-17A2D935DB39Q36728782-14E3ED26-12CB-4618-A253-C5BB6EE14EA0Q37173390-68951FBA-ACCD-4568-8B45-315CEAE975B6Q37242897-930DE799-80DE-4824-99F6-B76BCA23B4B8Q37453329-AE5EF22E-6620-4CCB-9366-C94B93922B46Q37478310-0B49041B-5DE5-4638-9F1D-5E62F044E102Q37544353-A5D6F57F-6679-4E17-AF50-6DBE8E8929C8Q37734486-ECD7C8E4-F173-4763-8C2F-7AF34075CBB9Q37811458-4D02B54D-7C67-4670-ABE0-1D70C91E8E32Q38067694-7128FA5D-37C2-41D0-BF39-A5FFAAA9360CQ38370342-41CC4C64-9C2A-445B-AA10-2A32A78A7979Q38415861-B6F6E3B6-E353-4C49-BD0E-6ED24207C24FQ38665326-66AE8B12-B338-4817-82F6-4B5D821B8DA0Q38779846-1315298D-C253-4D27-A046-B808B751E7F5Q38818062-C55877BD-4522-428B-8795-62403C367BF3Q39325580-CB02322A-37FA-46E6-9B46-4C8B0C3E1BE0Q39468197-680E7A08-957A-4247-A4F3-F7F3B1DCE324Q39735571-1B89ECF1-62DE-46BB-83F1-5F0B5F6C3B49Q39848377-A8688063-CF6E-4399-AE75-079041B5CA2AQ40348364-F5F08698-FA40-4CA7-92CF-D7FF823EEF2EQ40399325-4C641EA0-E25E-43A0-8121-DC40B2CF7D94Q40483485-D54507C2-978A-4A76-90E0-731F131DA077Q40501883-DCEB02FB-2BB5-41B9-8501-E4FD532FCD19Q40570063-04C3B2EC-DB4B-4A69-9029-3AA4A7C0BA1DQ40649144-328C7D2E-0D45-47C7-9094-F9D5CF46747BQ41742346-98BC62F7-47A0-4933-8A86-74629995A7BB
P2860
Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Cytomegalovirus UL97 phosphotr ...... susceptibility to ganciclovir.
@en
Cytomegalovirus UL97 phosphotr ...... susceptibility to ganciclovir.
@nl
type
label
Cytomegalovirus UL97 phosphotr ...... susceptibility to ganciclovir.
@en
Cytomegalovirus UL97 phosphotr ...... susceptibility to ganciclovir.
@nl
prefLabel
Cytomegalovirus UL97 phosphotr ...... susceptibility to ganciclovir.
@en
Cytomegalovirus UL97 phosphotr ...... susceptibility to ganciclovir.
@nl
P2093
P356
P1476
Cytomegalovirus UL97 phosphotr ...... susceptibility to ganciclovir.
@en
P2093
Anne E Senters
George W Kemble
Kevin S Michels
Rachel H Waldemer
Richard C Miner
Sunwen Chou
W Lawrence Drew
P304
P356
10.1086/338362
P407
P577
2001-12-17T00:00:00Z